Physician profile
Alison Donovan
NPI 1518375823
$1,353.30
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $636 · 2022: $141 · 2023: $544 · 2024: $32.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $326.25 | 2021-2023 | Descovy |
| Abbvie INC. | $322.46 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $109.18 | 2021 | |
| Merck Sharp & Dohme LLC | $89.42 | 2021-2023 | Gardasil 9 |
| Viiv Healthcare Company | $87.05 | 2023 | Apretude |
| Pfizer INC. | $63.32 | 2021-2023 | |
| Lilly USA, LLC | $54.75 | 2021 | |
| Tris Pharma INC | $44.64 | 2023 | Dyanavel Xr |
| Boston Scientific Corporation | $32.50 | 2024 | Wavewriter Alpha Prime 16 |
| Bausch Health US, LLC | $29.87 | 2023 | Wellbutrin |
| Therapeuticsmd, INC. | $24.80 | 2021 | |
| Astellas Pharma US INC | $23.84 | 2023 | Veozah |
| Novo Nordisk INC | $22.96 | 2023 | Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $22.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.78 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $22.53 | 2021 | |
| Daiichi Sankyo INC. | $22.00 | 2023 | Injectafer |
| Avion Pharmaceuticals | $16.11 | 2021 | |
| Genentech USA, INC. | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.